Trial reportGut2007
Effect of a second-generation alpha2delta ligand (pregabalin) on visceral sensation in hypersensitive patients with irritable bowel syndrome.
Trial report in Gut, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 75 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
75 citing papers in PubMed, 2 syntheses or guidelines pooled it, 200 citations in OpenAlex.
- Evidence-based clinical practice guidelines for irritable bowel syndrome.Journal of gastroenterology · 2015Guideline
- Systematic review of modulators of benzodiazepine receptors in irritable bowel syndrome: is there hope?World journal of gastroenterology · 2011Pooled it
- Trial
- Clinical Trial: Study to Investigate the Efficacy and Safety of the Alpha-2-Delta Ligand PD-217,014 in Patients With Irritable Bowel Syndrome.Alimentary pharmacology & therapeutics · 2025Trial
- Randomised clinical trial: pregabalin vs placebo for irritable bowel syndrome.Alimentary pharmacology & therapeutics · 2019Trial
- Pilot trial: pregabalin on colonic sensorimotor functions in irritable bowel syndrome.Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver · 2014Trial
- The analgesic effect of pregabalin in patients with chronic pain is reflected by changes in pharmaco-EEG spectral indices.British journal of clinical pharmacology · 2012Trial
- Effects of pregabalin on central sensitization in patients with chronic pancreatitis in a randomized, controlled trial.PloS one · 2012Trial
- Effect of the α2δ ligand, pregabalin, on colonic sensory and motor functions in healthy adults.American journal of physiology. Gastrointestinal and liver physiology · 2011Trial
- Irritable bowel syndrome.Nature reviews. Disease primers · 2026Review
- The Mast Cell-PAR2-TRP Axis: A Convergent Mechanism for Visceral Hypersensitivity Independent of Divergent Motility in IBS.Biomolecules · 2026Review
- Visceral Pain in Preterm Infants with Necrotizing Enterocolitis: Underlying Mechanisms and Implications for Treatment.Paediatric drugs · 2025Review
- Targeting γ-aminobutyric acid pathways in irritable bowel syndrome: bridging central nervous system, enteric dysfunction, and the microbiota-gut-brain axis.Frontiers in pharmacology · 2025Review
- Unveiling the efficacy of paroxetine and gabapentin in ulcerative colitis patients in remission with co-existing IBS-like symptoms: a single-blinded randomized clinical trial.Frontiers in medicine · 2024Article
- Expert Consensus on Ion Channel Drugs for Chronic Pain Treatment in China.Journal of pain research · 2024Review
- Low-level inflammation, immunity, and brain-gut axis in IBS: unraveling the complex relationships.Gut microbes · 2023Review
- Abdominal Pain in Inflammatory Bowel Disease: An Evidence-Based, Multidisciplinary Review.Crohn's & colitis 360 · 2023Article
- Management of Pelvic Pain in Patients with Crohn's Disease-Current Overview.Journal of clinical medicine · 2023Review
- Randomized clinical trial: the effects of pregabalin for centrally mediated abdominal pain syndrome.Therapeutic advances in gastroenterology · 2023Article
- Gut feelings: the microbiota-gut-brain axis on steroids.American journal of physiology. Gastrointestinal and liver physiology · 2022Review
15 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
6 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundVisceral hypersensitivity is an important pathophysiological factor in irritable bowel syndrome (IBS). Pre-clinical studies suggest that the alpha(2)delta ligand pregabalin reduces both visceral allodynia and hyperalgesia, but is inactive on basal sensitivity.
aimTo assess the effect of pregabalin on the perception of rectal distension in hypersensitive IBS patients.
methodsTwenty-six patients with Rome-II-defined IBS (aged 18-46 years, 7 male) were included in a randomized, double-blind, placebo-controlled, parallel-group study in which they received either 3 weeks oral pregabalin (titrated: 50 mg tid days 1-3, 100 mg tid days 4-7, 150 mg tid days 8-11; fixed 200 mg tid days 12-21 +/-4) or placebo control. Rectal sensitivity was assessed using a barostat technique, in which sensory thresholds were determined using the ascending method of limits, followed by tracking both before and after treatment. Only patients with a pain threshold of <or=28 mmHg were included in the study.
resultsPregabalin significantly increased the sensory thresholds from baseline for first sensation (p = 0.045), desire to defecate (p = 0.008) and pain (p = 0.048) compared with placebo control. In addition, pregabalin significantly increased rectal compliance (p<0.0001), although this appeared to be unrelated to the changes in sensitivity. Despite the occurrence of mild dizziness and somnolence, pregabalin was generally well tolerated.
conclusionsPregabalin increased distension sensory thresholds to normal levels in IBS patients with rectal hypersensitivity. A concomitant increase in rectal compliance appeared to be unrelated to the reduction in sensitivity. These data suggest that alpha(2)delta ligands are worthy of further investigation in the treatment of visceral pain disorders, including IBS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.